Iranian
Biomedical Journal
Volume 30, Issue 2 (Supplementary 2026)
IBJ 2026, 30(2): 40-40 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Molaei Zadeh M, Moaiedi S, Araghi M. Effect of Cold Plasma on Helicobacter pylori Inactivation and Its Role in Gastric Cancer Prevention. IBJ 2026; 30 (2) :40-40
URL: http://ibj.pasteur.ac.ir/article-1-5543-en.html
URL: http://ibj.pasteur.ac.ir/article-1-5543-en.html
Abstract:
Atmospheric cold plasma (ACP) has emerged as a promising technology in microbiology, particularly for treating infections and medical disinfection. It shows significant activity against Helicobacter pylori, a key pathogenic bacterium linked to chronic gastritis, peptic ulcers, and an increased risk of gastric cancer. The growing resistance of H. pylori to conventional antibiotics highlights the need for alternative therapeutic strategies, and ACP generates a variety of reactive species, including free radicals and charged ions, which can effectively inactivate H. pylori by disrupting cell membrane, inducing oxidative damage, and destabilizing biofilms. Existing laboratory studies confirm its ability to reduce bacterial load on surfaces and in biological samples, even against resistant strains, although variability in findings—due to different plasma sources, operating conditions, and experimental models—illustrates a lack of standardization in research. Current evidence supports ACP as a non-antibiotic method for inactivating H. pylori. Studies have indicated that its reactive species can disrupt cell membranes, alter metabolic processes, and weaken biofilms. However, the differences in outcomes emphasize the need for more standardized methodologies. This review article aims to summarize current evidence and examine the mechanisms, potential applications, and challenges of using cold plasma in the management of H. pylori-related infections. Despite its strong antimicrobial potential, limited data on safety, tissue interactions, and long-term effects necessitate further research to optimize parameters, improve comparability, and conduct clinically oriented evaluations. Ultimately, ACP exhibits significant anti-H. pylori potential through mechanisms such as membrane disruption, oxidative damage, and biofilm destabilization, positioning it as a promising adjunct or alternative to conventional therapies in light of rising antimicrobial resistance. Nonetheless, clinical validation of optimal dosing, safety, and long-term biological effects remains essential.
 |
Type of Study: Congress |
Subject:
Related Fields
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
IBJ is a member of Committee on Publication Ethics (COPE)
and follows its guidelines |
The articles of this journal are licensed under
a Creative Commons Attribution-NonDerivatives 4.0 International License. .png) |
 IBJ is owned and published by Pasteur Institute of Iran |